Table 3.
Responses to eculizumab therapy.
| Case | Day | Hb | Platelet | LDH | Cr | Extrarenal complications | Days to normal values∗ | Days to | |
|---|---|---|---|---|---|---|---|---|---|
| g/L | ×109/L | U/L | mg/dL | Platelet | LDH | CKD ↓ 1 stage | |||
| 1 | 0 | 83 | 134 | 884 | 1.13 | Intermittent confusion, and anasarca | ≤7 | >21 | >21 |
| 7 | 85 | 186 | 965 | 1.18 | Resolved | ||||
|
| |||||||||
| 2 | 0 | 98 | 81 | 902 | 3.47 | Somnolence, confusion, and vomiting | ≤7 | 70 | 378, 483 |
| 7 | 91 | 162 | 859 | 4.45 | Resolved | ||||
|
| |||||||||
| 3 | 0 | 86 | 131 | 1,235 | 5.12 | Headache, confusion, abdominal pain, nausea, and vomiting | ≤7 | 14 | 63 |
| 7 | 92 | 303 | 672 | 4.41 | Resolved and HTN stabilized | ||||
|
| |||||||||
| 4-1 | 0 | 71 | 105 | 250 | 3.79 | Anasarca, headache, and visual scotoma | 3 | 14 | 14 |
| 7 | 71 | 198 | NA | 2.66 | Resolved | ||||
| 4-2 | 0 | 84 | 63 | 770 | 5.52 | Nausea, vomiting, and dyspnea | 6 | 14 | 14 |
| 6 | 83 | 230 | 321 | NA | Resolved | ||||
|
| |||||||||
| 5 | 0 | 98 | 65 | 693 | 3.99 | Somnolence and intermittent confusion | >84 | >84 | >84 |
| 7 | 85 | 42 | 818 | 4.06 | No improvement | ||||
*Since the tests were not performed daily, the actual days may be less than the given values.
CKD: chronic kidney disease.